This study aims to determine the effects of Anaheal Bromelain on the clinical parameters of periodontal diseases in non-surgical treatment for the patients with moderate chronic periodontitis. The study was implemented as a double-blind, placebo-controlled, single center, phase-one trial. So that, a number of 80 patients aged 15 to 60 years old were admitted to the study with the following inclusion criteria: patients who suffer from moderate chronic periodontitis with clinical attachment loss (CAL) of 3 to 4 millimeters who were systemically healthy. Exclusion criteria for this study were as follows: Sensitivity to the medication (patients with sensitivity to pineapple, celery, carrot and fennel may also have sensitivity to Bromelain),History of cardiac diseases, Pregnant women, Gastrointestinal diseases such as peptic ulcer ,Renal or Hepatic Diseases, Coagulate anomalies such as hemophilia, Systemic lupus erythematous, Any history of periodontal treatment (scaling, root planning or surgery) at the past six months, Alcohol, cigarette or drug consumption, Concurrent Anti-coagulant or thrombolytic therapy. In the present study, patients were randomly divided into two groups of 40. Anaheal Bromelain was prescribed to one of the groups and the patients of the other group received a placebo. After charting, mouth hygiene instructions, scaling treatment and root planning carried out and indexes of clinical attachment loss (CAL), blood on probing (BOP), plaque index (PI) , plaque depth (PD)and gingival index(GI) were evaluated and recorded. Furthermore, the medication and placebo prescription after four and eight weeks, and synchronic non-surgical treatment and clinical parameters measurement were performed for patients and any improvement in clinical parameters was recorded according to the comparison between the values before and after the standard treatment and supplementary Anaheal Bromelain reception. BOP, CAL, PD and GI were measured by periodontal probe and plaque index was measured by disclosing tablets.